TDF Combined With LDT for the Treatment of HBeAg-positive Hepatitis B Patients With Poor Response to TDF for 12 Months

Last updated: January 8, 2021
Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hepatitis B

Hepatitis

Liver Disorders

Treatment

N/A

Clinical Study ID

NCT04650828
00000001
  • Ages 18-70
  • All Genders

Study Summary

Studies have shown that the HBeAg seroconversion rate of HBeAg positive chronic hepatitis B with tenofovir for one year's treatment was 17.8% and the negative conversion rate of their HBeAg and HBV DNA were 20.0% and 97.6%. The HBeAg Seroconversion rate of these patients was lower.Clinically, most patients need to take tenofovir for a long time, which may cause serious complications such as renal function damage,with decreased therapy compliance and Increased cost of treatment.In the course of tenofovir treatment, it is common that HBV-DNA negative patients with HBeAg Being down poor or staying at a low positive level for a long time keep taking the medicine. Therefore, it is Significant to Increase the HBeAg seroconversion rate of tenofovir during the clinical treatment.

Telbivudine has a strong antiviral effect.Studies have shown that the HBeAg seroconversion rate of HBeAg positive CHB for one year was 25%, which was higher than other nucleosides, and it could also improve the damaged renal function to a certain extent.The HBeAg seroconversion rate of patients with poor response to tenofovir for 12 months could be still poor if for 24 months . Therefore, this study is to observe the efficacy of these patients combined with telbivudine.

Eligibility Criteria

Inclusion

Inclusion criteria:

  1. Male or female patients, aged 18 to 70 years, including 18 and 70 years old;
  2. Patients with poor response to tenofovir for 12 months did not obtained HBeAgseroconversionPatients with poor response to tenofovir for 12 months who didn't obtainHBeAg seroconversion choosed to continue taking tenofovir or take tenofovir combinedwith Tbl for 12months;
  3. Persons were willing to sign informed consent and comply with medication regimen andfollow-up.

Exclusion

Exclusion Criteria:

  1. Co-infectious with hepatitis A, hepatitis C, hepatitis D, hepatitis E or HIV;
  2. In the decompensated stage of liver cirrhosis, such as ascites, varicose bleeding orhepatic encephalopathy;
  3. With malignant tumors (including hepatocellular carcinoma);
  4. Concomitant with other liver diseases, such as alcoholic liver disease, autoimmunedisease, or other systemic diseases involving the liver, such as hemochromatosis,Alpha-1 antitrypsin deficiency, or Wilson disease;
  5. During the study period, chronic systemic steroid drugs are required or may be usedunder any medical conditions; There are any other factors that the researcher thinks are not suitable for inclusion inthe study, or that may affect the patient's participation or completion of the study.

Study Design

Total Participants: 200
Study Start date:
December 01, 2020
Estimated Completion Date:
December 30, 2022

Study Description

This is an open, multicenter, exploratory and real-world clinical study. It will be carried out in patients with poor response (HBV DNA > 2x103iu / ml) to tenofovir for 12 months. After one -week screening period, patients will be randomly assigned 1:1 to control and experimental groups. The control group takes tenofovir for 12 months while the experimental group takes tenofovir combined with telbivudinefor 12months .

Connect with a study center

  • Chaoshuang Lin

    Guangzhou,
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.